利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

494 条记录 (耗时 0.03 秒)

    MATURE DENDRITIC CELL COMPOSITIONS AND METHODS FOR CULTURING SAME
    81.
    发明授权
    MATURE DENDRITIC CELL COMPOSITIONS AND METHODS FOR CULTURING SAME 有权
    ZUSAMMENSETZUNGEN REIFER DENDRITISCHER ZELLEN UND VERFAHREN ZU DEREN KULTIVIERUNG

    公开(公告)号：EP1809737B9

    公开(公告)日：2011-10-05

    申请号：EP05804341.5

    申请日：2005-10-07

    申请人： Argos Therapeutics, Inc.

    发明人： HEALEY, Don ,  TCHEREPANOVA, Irina ,  ADAMS, Melissa ,  HINOHARA, Atsushi

    IPC分类号： C12N5/0784 ,  A61K39/00

    CPC分类号： C12N5/0639 ,  A61K2039/5154 ,  C12N15/87 ,  C12N2500/36 ,  C12N2501/02 ,  C12N2501/22 ,  C12N2501/23 ,  C12N2501/24 ,  C12N2501/52 ,  C12N2510/00

    摘要： This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-³R) agonist and/or a tumor necrosis factor alpha receptor (TNF-±R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g. mRNA or DNA), an agonistic antibody to CD40 receptor or by CD40 ligand polypeptide. The enriched populations can be further modified by the administration of an immunogen to the DC. The DC will take up and process the immunogen on its cell surface.

    摘要翻译： 本发明提供了制备和使用免疫刺激细胞增强免疫应答的方法。 本发明提供了一种制备成熟树突状细胞（DC）的方法，包括以下顺序步骤：（a）用包含干扰素γ受体（IFN-3R）激动剂和/或 肿瘤坏死因子α受体（TNF-R）激动剂产生信号传导的树突状细胞; 和（b）用包含有效量的CD40激动剂的第二瞬时信号发信号通知所述信号传导的树突状细胞以产生CCR7 +成熟树突状细胞。 本发明还提供了通过本发明的方法制备的富含树枝状细胞的群体。 这种树突状细胞具有增强的免疫刺激性能和增加的IL-12分泌和/或降低的IL-10分泌。 可以由编码CD40L（例如mRNA或DNA）的外源多核苷酸，CD40受体的激动性抗体或CD40配体多肽翻译的一种或多种多肽来启动CD40信号传导。 通过向DC施用免疫原可以进一步修饰富集的群体。 DC将占据并处理细胞表面的免疫原。

    RAPID ONE-STEP METHOD FOR GENERATION OF ANTIGEN LOADED DENDRITIC CELL VACCINE FROM PRECURSORS
    82.
    发明授权
    RAPID ONE-STEP METHOD FOR GENERATION OF ANTIGEN LOADED DENDRITIC CELL VACCINE FROM PRECURSORS 有权
    一种制造负载抗原DENDRITENZELLIMPFSTOFFS由前体的单级方法FAST

    公开(公告)号：EP1567014B1

    公开(公告)日：2011-09-28

    申请号：EP03808435.6

    申请日：2003-12-04

    申请人： Baylor Research Institute

    发明人： BANCHEREAU, Jacques, F. ,  PALUCKA, Anna K.

    IPC分类号： A01N63/00 ,  A61K45/00 ,  A61K47/00 ,  C12N5/00 ,  C12N5/02 ,  C12N5/0784

    CPC分类号： A61K39/0011 ,  A61K2039/5152 ,  A61K2039/5154 ,  C12N5/0639 ,  C12N2501/22 ,  C12N2501/25

    摘要： A one-step method for producing antigen loaded antigen-presenting cells from monocytes ex vivo has been found which comprises contacting the monocytes with a composition comprising an activator such as TNF alpha preferably in combination with at least one growth factor such as GM-CSF and at least one soluble or particulate antigen. According to the methods of the present invention, antigen-loaded dendritic cell vaccines can be generated within as little as three (3) days. In another method of the present invention, antigen loaded antigen-presenting cells are produced from monocytes ex vivo by contacting the monocytes with TNF alpha and granulocyte-macrophage colony stimulating factor at one time point to form antigen-presenting cells and then contacting antigen­presenting cells with soluble or particulate antigenic material at a second time point to form antigen loaded antigen-presenting cells, wherein the antigen loaded antigen-presenting cells are produced in less than four days. The present invention also includes a vaccine which comprises monocyte-derived antigen loaded antigen-presenting cells, wherein the antigen­presenting cells are composed of two or more subsets selected from the group consisting of Langerhans cells with surface markers (CD 1 a+ CD207+); interstitial dendritic cells with surface markers (CD 1a+ CD207-); double negative dendritic cells with surface markers 20 (CD 1 a-CD 14-); and dendritic cells with surface markers (CD 14+ CD 1 a- CD209+).

    ANTI-TUMOR VACCINE DERIVED FROM NORMAL CHEMICALLY MODIFIED CD4+ CELLS
    83.
    发明授权
    ANTI-TUMOR VACCINE DERIVED FROM NORMAL CHEMICALLY MODIFIED CD4+ CELLS 有权
    抗肿瘤疫苗正常化学修饰细胞CD4 +

    公开(公告)号：EP2102331B1

    公开(公告)日：2011-08-31

    申请号：EP08701232.4

    申请日：2008-01-03

    申请人： CytoVac A/S

    发明人： KIRKIN, Alexei ,  DZHANDZHUGAZYAN, Karine

    IPC分类号： C12N5/0784 ,  A61K45/00 ,  A61P35/00

    CPC分类号： C12N5/0636 ,  A61K39/0011 ,  A61K2039/5158 ,  A61K2039/572 ,  C12N5/0637 ,  C12N2501/06 ,  C12N2501/23 ,  C12N2502/1121

    摘要： A composition for inducing an immune response in a mammal, comprises lymphoid cells in which expression of tumor antigens has been chemically induced. The tumor antigens are induced in proliferating normal lymphoid cells, especially during the log phase of proliferation. The proliferation of the normal lymphoid cells is stimulated by normal mature dendritic cells. Most conveniently, the lymphoid cells are lymphocytes, especially peripheral blood lymphocytes. The tumor antigens are typically cancer/testis antigens, which may be chemically induced by DNA demethylation. Cancer/testis antigens are expressed in a wide range of tumors, so the composition is able to raise an immune response that is effective against a wide range of tumors, despite the fact that it is derived from normal cells. The composition may be used for preparation of an anti-tumor vaccine for prophylactic or therapeutic use. The composition may also be used for ex vivo activation of cytotoxic T lymphocytes, followed by expansion of the cytotoxic T lymphocyte population by normal dendritic cells, for cancer treatment by adoptive T cell immunotherapy.

    Compositions and methods for producing antigen-presenting cells
    85.
    发明公开
    Compositions and methods for producing antigen-presenting cells 审中-公开
    Zusammensetzungen und Verfahren zur Herstellung vonAntigenpräsentierendenZellen

    公开(公告)号：EP2269629A2

    公开(公告)日：2011-01-05

    申请号：EP10010087.4

    申请日：2001-05-11

    申请人： Baylor Research Institute

    发明人： Bancheraeu, Jacques F. ,  Mohamadzadeh, Mansour ,  Palucka, Anna Karolina

    IPC分类号： A61K38/20 ,  A61K38/19 ,  A61K38/18 ,  C12N5/0784

    CPC分类号： C12N5/0639 ,  A61K2039/5154 ,  C12N2501/052 ,  C12N2501/056 ,  C12N2501/15 ,  C12N2501/22 ,  C12N2501/23 ,  C12N2501/25 ,  C12N2501/52

    摘要： The present invention relates to compositions and methods for producing antigen-presenting cells, in vitro, ex vivo or in vivo. This invention relates more particularly to methods and compositions for producing dendritic cells using interleukin-15, preferably in combination with a growth factor such as GM-CSF. This invention is particularly suited for producing immature dendritic cells and activated cells from precursors, in vitro, ex vivo or in vivo. The invention also relates to compositions for implementing these methods, as well as compositions comprising antigen-presenting cells and uses thereof. Dendritic cells or membrane vesicles derived thereforom have utility in many applications, including diagnostic, therapy, vaccination, research, screening and gene delivery.

    摘要翻译： 本发明涉及体外，离体或体内产生抗原呈递细胞的组合物和方法。 本发明更具体地涉及使用白细胞介素-15，优选与生长因子例如GM-CSF组合产生树突状细胞的方法和组合物。 本发明特别适于从体外，离体或体内从前体产生未成熟树突状细胞和活化细胞。 本发明还涉及用于实施这些方法的组合物，以及包含抗原呈递细胞的组合物及其用途。 衍生自其的树突状细胞或膜囊可用于许多应用，包括诊断，治疗，疫苗接种，研究，筛选和基因递送。

    MATURE DENDRITIC CELL COMPOSITIONS AND METHODS FOR CULTURING SAME
    86.
    发明授权
    MATURE DENDRITIC CELL COMPOSITIONS AND METHODS FOR CULTURING SAME 有权
    成分成熟树突状细胞和培养方法

    公开(公告)号：EP1809737B1

    公开(公告)日：2010-11-24

    申请号：EP05804341.5

    申请日：2005-10-07

    申请人： Argos Therapeutics, Inc.

    发明人： HEALEY, Don ,  TCHEREPANOVA, Irina ,  ADAMS, Melissa ,  HINOHARA, Atsushi

    IPC分类号： C12N5/0784 ,  A61K39/00

    CPC分类号： C12N5/0639 ,  A61K2039/5154 ,  C12N15/87 ,  C12N2500/36 ,  C12N2501/02 ,  C12N2501/22 ,  C12N2501/23 ,  C12N2501/24 ,  C12N2501/52 ,  C12N2510/00

    摘要： This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-³R) agonist and/or a tumor necrosis factor alpha receptor (TNF-±R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g. mRNA or DNA), an agonistic antibody to CD40 receptor or by CD40 ligand polypeptide. The enriched populations can be further modified by the administration of an immunogen to the DC. The DC will take up and process the immunogen on its cell surface.